{"protocolSection": {"identificationModule": {"nctId": "NCT00856284", "orgStudyIdInfo": {"id": "SYR-322_305"}, "secondaryIdInfos": [{"id": "2008-007444-34", "type": "REGISTRY", "domain": "EudraCT"}, {"id": "U1111-1111-7397", "type": "REGISTRY", "domain": "WHO"}, {"id": "HKCTR-862", "type": "REGISTRY", "domain": "HKUCTR"}, {"id": "DOH-27-0709-2825", "type": "REGISTRY", "domain": "SANCTR"}, {"id": "09/H0703/66", "type": "REGISTRY", "domain": "NRES"}, {"id": "NMRR-09-203-3590", "type": "REGISTRY", "domain": "NMRR"}], "organization": {"fullName": "Takeda", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus", "officialTitle": "A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination With Metformin in Subjects With Type 2 Diabetes", "acronym": "ENDURE"}, "statusModule": {"statusVerifiedDate": "2013-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-03"}, "primaryCompletionDateStruct": {"date": "2012-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-03-04", "studyFirstSubmitQcDate": "2009-03-04", "studyFirstPostDateStruct": {"date": "2009-03-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-09-25", "resultsFirstSubmitQcDate": "2013-09-25", "resultsFirstPostDateStruct": {"date": "2013-12-03", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2013-02-11", "dispFirstSubmitQcDate": "2013-02-17", "dispFirstPostDateStruct": {"date": "2013-02-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-09-25", "lastUpdatePostDateStruct": {"date": "2013-12-03", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Takeda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.", "detailedDescription": "For patients diagnosed with type 2 diabetes mellitus, metformin is the usual first-line therapy in addition to diet control and exercise. For those patients with inadequate glycemic control with metformin monotherapy or experiencing serious side effects of metformin, sulfonylurea is a popular choice as a second-line oral antidiabetic treatment.\n\nAlogliptin is a dipeptidyl peptidase-4 inhibitor currently being developed by Takeda for use in patients with type 2 diabetes mellitus.\n\nThis study is designed to further explore the durability of efficacy and safety of alogliptin compared to glipizide in type 2 diabetes mellitus patients whose blood sugar level is inadequately controlled with metformin therapy.\n\nThe duration of this study will be approximately 2 years."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Diabetes Mellitus", "Drug Therapy", "Hyperinsulinism", "Hyperglycemia", "Glucose Intolerance"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 2639, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Metformin + Alogliptin 12.5 mg", "type": "EXPERIMENTAL", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.", "interventionNames": ["Drug: Alogliptin", "Drug: Metformin"]}, {"label": "Metformin + Alogliptin 25 mg", "type": "EXPERIMENTAL", "description": "Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.", "interventionNames": ["Drug: Alogliptin", "Drug: Metformin"]}, {"label": "Metformin + Glipizide", "type": "ACTIVE_COMPARATOR", "description": "Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose \u2265250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.", "interventionNames": ["Drug: Metformin", "Drug: Glipizide"]}], "interventions": [{"type": "DRUG", "name": "Alogliptin", "description": "Alogliptin tablets", "armGroupLabels": ["Metformin + Alogliptin 12.5 mg", "Metformin + Alogliptin 25 mg"], "otherNames": ["SYR-322", "Nesina"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin tablets", "armGroupLabels": ["Metformin + Alogliptin 12.5 mg", "Metformin + Alogliptin 25 mg", "Metformin + Glipizide"], "otherNames": ["Glucophage"]}, {"type": "DRUG", "name": "Glipizide", "description": "Glipizide tablets", "armGroupLabels": ["Metformin + Glipizide"], "otherNames": ["Glucotrol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52", "description": "The change from Baseline to Week 52 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104", "description": "The change from Baseline to Week 104 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.", "timeFrame": "Baseline and Week 104"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin at Other Time Points", "description": "The change from Baseline over time in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.", "timeFrame": "Baseline and Weeks 4, 8, 12, 16, 20, 26, 39, 65, 78, and 91."}, {"measure": "Change From Baseline in Fasting Plasma Glucose Over Time", "description": "The change from Baseline in fasting plasma glucose (FPG) was assessed at Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104. LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline FPG and Baseline metformin dose as covariates.", "timeFrame": "Baseline and Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104."}, {"measure": "Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%", "description": "The percentage of participants with HbA1c less than or equal to 6.5% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.", "timeFrame": "Weeks 26, 52, 78, and 104."}, {"measure": "Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%", "description": "Percentage of participants with HbA1c \u2264 7.0% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.", "timeFrame": "Weeks 26, 52, 78, and 104."}, {"measure": "Change From Baseline in Body Weight Over Time", "description": "LS Means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and Baseline weight and Baseline metformin dose as covariates.", "timeFrame": "Baseline and Weeks 12, 26, 39, 52, 65, 78, 91, and 104."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Has a diagnosis of type 2 diabetes mellitus.\n* Must meet one of the following:\n\n  * Has been inadequately controlled on a stable daily dose of \u22651500 mg (or documented maximum tolerated dose) of metformin for at least 2 months prior to Screening.\n  * Has been inadequately controlled (as defined by a glycosylated hemoglobin 7.5 - 10%, inclusive) on metformin \\<1500 mg without documented maximum tolerated dose.\n* No treatment with antidiabetic agents other than metformin within 2 months prior to Screening (for Schedule A)/Pre-Screening (for Schedule B).\n* Has body mass index within 23 kg/m\\^2 and 45 kg/m\\^2 unless the patient is Asian or of Asian descent, for whom the allowable body mass index will be \u2265 20 kg/m\\^2 and \u2264 35 kg/m\\^2, inclusive.\n* Has fasting C-peptide concentration at least 0.8 ng.\n* If regularly using non-excluded medications, must be on a stable dose at least 4 weeks prior to Screening/Pre-screening.\n* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant, lactating or intends to donate ova from Screening throughout the duration of the study.\n* Must be able and willing to monitor their blood glucose concentrations with a home monitor, and comply with protocol requirements including scheduled clinic appointments.\n\nExclusion Criteria:\n\n* Systolic blood pressure greater than or equal to 150 mmHg and/or diastolic pressure greater than or equal to 90.\n* Hemoglobin less than or equal to 12 g/dL for males and less than or equal to 10 g/dL for females at Screening Visit.\n* Alanine aminotransferase greater than or equal to 2.5 times the upper limit of normal at Screening Visit.\n* Serum creatinine greater than or equal to 1.5 mg/dL for males and 1.4 for females, or calculated creatinine clearance less than 60 L/min.\n* Males intending to impregnate others or donate sperm before, during or within 1 month after participating in the study.\n* A history of cancer other than squamous or basal cell carcinoma of the skin that has not been in full remission for at least 5 years.\n* A history of laser treatment for diabetic retinopathy within 6 months of screening.\n* Treated for diabetic gastric paresis, gastric banding, or gastric bypass.\n* New York Heart Association Class III or IV heart failure.\n* History of coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, stroke or transient ischemic attack within 3 months prior to screening.\n* Known history of human immunodeficiency virus, hepatitis B or C.\n* Alcohol or substance abuse within 2 years prior to screening.\n* Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:\n\n  * Any investigational drug within 30 days\n  * Any investigational diabetic drug within 3 months\n  * Any antidiabetic drug in the dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 mimetics classes within 90 days prior to Screening other than metformin\n  * Prior treatment with alogliptin.\n  * Weight-loss drugs\n  * Oral or systemically injected glucocorticoids\n* A hypersensitivity allergy or anaphylactic reaction to any dipeptidyl peptidase-4 drug, metformin or glipizide.\n* Has a documented history or concurrent signs of significant thyroid disease (eg, autoimmune thyroid diseases such as Graves disease and Hashimoto thyroiditis or active thyroid nodules).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director, Clinical Science", "affiliation": "Takeda", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Montgomery", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 32.36681, "lon": -86.29997}}, {"city": "Muscle Shoals", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 34.74481, "lon": -87.66753}}, {"city": "Pell City", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.58621, "lon": -86.28609}}, {"city": "Mesa", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.42227, "lon": -111.82264}}, {"city": "Peoria", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.5806, "lon": -112.23738}}, {"city": "Phoenix", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"city": "Sierra Vista", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 31.55454, "lon": -110.30369}}, {"city": "Tempe", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.41477, "lon": -111.90931}}, {"city": "Tucson", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"city": "Anaheim", "state": "California", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"city": "Artesia", "state": "California", "country": "United States", "geoPoint": {"lat": 33.86585, "lon": -118.08312}}, {"city": "Chico", "state": "California", "country": "United States", "geoPoint": {"lat": 39.72849, "lon": -121.83748}}, {"city": "Los Alamitos", "state": "California", "country": "United States", "geoPoint": {"lat": 33.80307, "lon": -118.07256}}, {"city": "Mission Viejo", "state": "California", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"city": "National City", "state": "California", "country": "United States", "geoPoint": {"lat": 32.67811, "lon": -117.0992}}, {"city": "Northridge", "state": "California", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"city": "Pismo Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 35.14275, "lon": -120.64128}}, {"city": "Riverside", "state": "California", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"city": "Roseville", "state": "California", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"city": "Sacramento", "state": "California", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"city": "Santa Monica", "state": "California", "country": "United States", "geoPoint": {"lat": 34.01945, "lon": -118.49119}}, {"city": "Tustin", "state": "California", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"city": "Arvada", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.80276, "lon": -105.08748}}, {"city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"city": "Ridgefield", "state": "Connecticut", "country": "United States", "geoPoint": {"lat": 41.28148, "lon": -73.49818}}, {"city": "Waterbury", "state": "Connecticut", "country": "United States", "geoPoint": {"lat": 41.55815, "lon": -73.0515}}, {"city": "Brooksville", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.55554, "lon": -82.38991}}, {"city": "New Port Richey", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.24418, "lon": -82.71927}}, {"city": "North Miami Beach", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.93315, "lon": -80.16255}}, {"city": "Ocala", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.1872, "lon": -82.14009}}, {"city": "Opa Locka", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.90232, "lon": -80.25033}}, {"city": "Orlando", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"city": "Augusta", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.47097, "lon": -81.97484}}, {"city": "Savannah", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"city": "Addison", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.9317, "lon": -87.98896}}, {"city": "Chicago", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"city": "Bloomington", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 39.16533, "lon": -86.52639}}, {"city": "Evansville", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 37.97476, "lon": -87.55585}}, {"city": "Indianapolis", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"city": "Mishawaka", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 41.66199, "lon": -86.15862}}, {"city": "South Bend", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 41.68338, "lon": -86.25001}}, {"city": "Lexington", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"city": "Munfordville", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 37.27228, "lon": -85.89108}}, {"city": "Marrero", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 29.89937, "lon": -90.10035}}, {"city": "Bangor", "state": "Maine", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"city": "Elkridge", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.21261, "lon": -76.71358}}, {"city": "Oxon Hill", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 38.80345, "lon": -76.9897}}, {"city": "North Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"city": "Ann Arbor", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"city": "Flint", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 43.01253, "lon": -83.68746}}, {"city": "Picayune", "state": "Mississippi", "country": "United States", "geoPoint": {"lat": 30.52556, "lon": -89.67788}}, {"city": "Springfield", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 37.21533, "lon": -93.29824}}, {"city": "St Peters", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.80033, "lon": -90.62651}}, {"city": "St. Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"city": "Omaha", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"city": "Las Vegas", "state": "Nevada", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"city": "Albuquerque", "state": "New Mexico", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"city": "New Windsor", "state": "New York", "country": "United States", "geoPoint": {"lat": 41.47676, "lon": -74.02375}}, {"city": "New York", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"city": "Rochester", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"city": "Fargo", "state": "North Dakota", "country": "United States", "geoPoint": {"lat": 46.87719, "lon": -96.7898}}, {"city": "Beachwood", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.4645, "lon": -81.50873}}, {"city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"city": "Dayton", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.75895, "lon": -84.19161}}, {"city": "Willoughby Hills", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.59838, "lon": -81.41845}}, {"city": "Zanesville", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.94035, "lon": -82.01319}}, {"city": "Norman", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.22257, "lon": -97.43948}}, {"city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"city": "Havertown", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.98095, "lon": -75.30852}}, {"city": "Norristown", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.1215, "lon": -75.3399}}, {"city": "Philadelphia", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"city": "Pittsburgh", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"city": "Tipton", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.6359, "lon": -78.29585}}, {"city": "Anderson", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.50344, "lon": -82.65013}}, {"city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"city": "Greer", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.93873, "lon": -82.22706}}, {"city": "Rapid City", "state": "South Dakota", "country": "United States", "geoPoint": {"lat": 44.08054, "lon": -103.23101}}, {"city": "New Tazewell", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.44258, "lon": -83.59963}}, {"city": "Arlington", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.73569, "lon": -97.10807}}, {"city": "Carrollton", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.95373, "lon": -96.89028}}, {"city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"city": "Fort Worth", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"city": "Hurst", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.82346, "lon": -97.17057}}, {"city": "Katy", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.78579, "lon": -95.8244}}, {"city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"city": "Spring", "state": "Texas", "country": "United States", "geoPoint": {"lat": 30.07994, "lon": -95.41716}}, {"city": "Temple", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.09823, "lon": -97.34278}}, {"city": "Midvale", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.61106, "lon": -111.89994}}, {"city": "Hampton", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.02987, "lon": -76.34522}}, {"city": "Lewisburg", "state": "West Virginia", "country": "United States", "geoPoint": {"lat": 37.80179, "lon": -80.44563}}, {"city": "Milwaukee", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"city": "Mar del Plata", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"city": "Garran", "state": "Australian Capital Territory", "country": "Australia", "geoPoint": {"lat": -35.34206, "lon": 149.10846}}, {"city": "Wollongong", "state": "New South Wales", "country": "Australia", "geoPoint": {"lat": -34.424, "lon": 150.89345}}, {"city": "Herston", "state": "Queensland", "country": "Australia", "geoPoint": {"lat": -27.44453, "lon": 153.01852}}, {"city": "Nedlands", "state": "Western Australia", "country": "Australia", "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"city": "Graz", "country": "Austria", "geoPoint": {"lat": 47.06667, "lon": 15.45}}, {"city": "Salzburg", "country": "Austria", "geoPoint": {"lat": 47.79941, "lon": 13.04399}}, {"city": "Recife", "state": "Pernambuco", "country": "Brazil", "geoPoint": {"lat": -8.05389, "lon": -34.88111}}, {"city": "Bras\u00edlia - DF", "state": "Planalto Central", "country": "Brazil"}, {"city": "Mogi das Cruzes", "state": "S\u00e3o Paulo", "country": "Brazil", "geoPoint": {"lat": -23.52278, "lon": -46.18833}}, {"city": "Fortaleza", "country": "Brazil", "geoPoint": {"lat": -3.71722, "lon": -38.54306}}, {"city": "S\u00e3o Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"city": "St. John's", "state": "Newfoundland and Labrador", "country": "Canada", "geoPoint": {"lat": 47.56494, "lon": -52.70931}}, {"city": "Brampton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.68341, "lon": -79.76633}}, {"city": "Collingwood", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 44.4834, "lon": -80.21638}}, {"city": "Corunna", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 42.88398, "lon": -82.45336}}, {"city": "Etobichoke", "state": "Ontario", "country": "Canada"}, {"city": "Etobicoke", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.65421, "lon": -79.56711}}, {"city": "Mississauga", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"city": "Smith Falls", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 44.90452, "lon": -76.02333}}, {"city": "Smiths Falls", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 44.90452, "lon": -76.02333}}, {"city": "Toronto", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"city": "Granby", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -72.73243}}, {"city": "Montreal", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"city": "Providencia", "state": "Santiago", "country": "Chile", "geoPoint": {"lat": -33.43107, "lon": -70.60454}}, {"city": "Santiago", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"city": "Potsdam", "state": "Brandenburg", "country": "Germany", "geoPoint": {"lat": 52.39886, "lon": 13.06566}}, {"city": "Kelkheim", "state": "Hesse", "country": "Germany"}, {"city": "Offenbach", "state": "Hesse", "country": "Germany", "geoPoint": {"lat": 50.10061, "lon": 8.76647}}, {"city": "M\u00fcnster", "state": "North Rhine-Westphalia", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"city": "Mainz", "state": "Rhineland-Palatinate", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"city": "Neuwied", "state": "Rhineland-Palatinate", "country": "Germany", "geoPoint": {"lat": 50.4336, "lon": 7.47057}}, {"city": "Rhaunen", "state": "Rhineland-Palatinate", "country": "Germany", "geoPoint": {"lat": 49.86322, "lon": 7.34232}}, {"city": "Guatemala City", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"city": "Wong Tai Sin", "state": "Kowloon", "country": "Hong Kong", "geoPoint": {"lat": 22.35, "lon": 114.18333}}, {"city": "Pok Fu Lam", "state": "Southern District", "country": "Hong Kong"}, {"city": "Kowloon", "country": "Hong Kong", "geoPoint": {"lat": 22.31667, "lon": 114.18333}}, {"city": "P\u00e9cs", "state": "Baranya", "country": "Hungary", "geoPoint": {"lat": 46.08333, "lon": 18.23333}}, {"city": "Miskolc", "state": "Borsod-Aba\u00faj-Zempl\u00e9n", "country": "Hungary", "geoPoint": {"lat": 48.1, "lon": 20.78333}}, {"city": "Kalocsa", "state": "B\u00e1cs-Kiskun", "country": "Hungary", "geoPoint": {"lat": 46.52639, "lon": 18.98583}}, {"city": "Gyula", "state": "B\u00e9k\u00e9s", "country": "Hungary", "geoPoint": {"lat": 46.65, "lon": 21.28333}}, {"city": "Mak\u00f3", "state": "Csongr\u00e1d", "country": "Hungary", "geoPoint": {"lat": 46.21667, "lon": 20.48333}}, {"city": "Szentes", "state": "Csongr\u00e1d", "country": "Hungary", "geoPoint": {"lat": 46.65628, "lon": 20.27194}}, {"city": "Ny\u00edregyh\u00e1za", "state": "Szabolcs-Szatm\u00e1r-Bereg", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"city": "Zalaegerszeg", "state": "Zala", "country": "Hungary", "geoPoint": {"lat": 46.84, "lon": 16.84389}}, {"city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"city": "Hyderabad", "state": "Andhra Pradesh", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"city": "Patna", "state": "Bihar", "country": "India", "geoPoint": {"lat": 25.59408, "lon": 85.13563}}, {"city": "Karnal", "state": "Haryana", "country": "India", "geoPoint": {"lat": 29.69197, "lon": 76.98448}}, {"city": "Bangalore", "state": "Karnataka", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"city": "Belgaum", "state": "Karnataka", "country": "India", "geoPoint": {"lat": 15.85212, "lon": 74.50447}}, {"city": "Bhopal", "state": "Madhya Pradesh", "country": "India", "geoPoint": {"lat": 23.25469, "lon": 77.40289}}, {"city": "Mumbai", "state": "Maharashtra", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"city": "Trichy", "state": "Tamil Nadu", "country": "India", "geoPoint": {"lat": 10.8155, "lon": 78.69651}}, {"city": "Kfar-Saba", "state": "Center District", "country": "Israel", "geoPoint": {"lat": 32.175, "lon": 34.90694}}, {"city": "Kfar Saba", "state": "Central District", "country": "Israel", "geoPoint": {"lat": 32.175, "lon": 34.90694}}, {"city": "Matan", "state": "Central District", "country": "Israel", "geoPoint": {"lat": 32.15856, "lon": 34.97413}}, {"city": "Petach Tikva", "state": "Central District", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"city": "Hadera", "state": "Haifa District", "country": "Israel", "geoPoint": {"lat": 32.44192, "lon": 34.9039}}, {"city": "Haifa", "state": "Haifa District", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"city": "Nahariya", "state": "Northern District", "country": "Israel", "geoPoint": {"lat": 33.00892, "lon": 35.09814}}, {"city": "Safed", "state": "Northern District", "country": "Israel", "geoPoint": {"lat": 32.96465, "lon": 35.496}}, {"city": "Ashkelon", "state": "Southern District", "country": "Israel", "geoPoint": {"lat": 31.66926, "lon": 34.57149}}, {"city": "Be'er Sheva", "state": "Southern District", "country": "Israel", "geoPoint": {"lat": 31.25181, "lon": 34.7913}}, {"city": "Holon", "state": "Tel Aviv", "country": "Israel", "geoPoint": {"lat": 32.01034, "lon": 34.77918}}, {"city": "Tel- Aviv", "state": "Tel Aviv", "country": "Israel", "geoPoint": {"lat": 32.08088, "lon": 34.78057}}, {"city": "Jerusalem", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"city": "Zefat", "country": "Israel", "geoPoint": {"lat": 32.96465, "lon": 35.496}}, {"city": "Milano", "state": "Milan", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"city": "Perugia", "country": "Italy", "geoPoint": {"lat": 43.1122, "lon": 12.38878}}, {"city": "Pistoia", "country": "Italy", "geoPoint": {"lat": 43.93064, "lon": 10.92365}}, {"city": "Gwangju", "state": "Honam", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"city": "Daejeon", "state": "Hoseo", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"city": "Daegu", "state": "Yeongnam", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"city": "Daugavpils", "country": "Latvia", "geoPoint": {"lat": 55.88333, "lon": 26.53333}}, {"city": "Liepaja", "country": "Latvia", "geoPoint": {"lat": 56.51667, "lon": 21.01667}}, {"city": "Limbazi", "country": "Latvia", "geoPoint": {"lat": 57.51287, "lon": 24.71941}}, {"city": "Ogre", "country": "Latvia", "geoPoint": {"lat": 56.8162, "lon": 24.61401}}, {"city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"city": "Talsi", "country": "Latvia", "geoPoint": {"lat": 57.24562, "lon": 22.58137}}, {"city": "Tukums", "country": "Latvia", "geoPoint": {"lat": 56.96694, "lon": 23.15528}}, {"city": "Valmiera", "country": "Latvia", "geoPoint": {"lat": 57.54108, "lon": 25.42751}}, {"city": "Alytus", "country": "Lithuania", "geoPoint": {"lat": 54.39636, "lon": 24.04143}}, {"city": "Kaunas", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"city": "Kedainiai", "country": "Lithuania", "geoPoint": {"lat": 55.28782, "lon": 23.97276}}, {"city": "Klaipeda", "country": "Lithuania", "geoPoint": {"lat": 55.70888, "lon": 21.14311}}, {"city": "Palanga", "country": "Lithuania", "geoPoint": {"lat": 55.9175, "lon": 21.06861}}, {"city": "Panevezys", "country": "Lithuania", "geoPoint": {"lat": 55.73333, "lon": 24.35}}, {"city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"city": "Ipoh", "country": "Malaysia", "geoPoint": {"lat": 4.5841, "lon": 101.0829}}, {"city": "Kajang", "country": "Malaysia", "geoPoint": {"lat": 2.99424, "lon": 101.78875}}, {"city": "Kota Bahru", "country": "Malaysia", "geoPoint": {"lat": 6.13328, "lon": 102.2386}}, {"city": "Kota Bharu", "country": "Malaysia", "geoPoint": {"lat": 6.13328, "lon": 102.2386}}, {"city": "Kuala Terengganu", "country": "Malaysia", "geoPoint": {"lat": 5.3302, "lon": 103.1408}}, {"city": "Kuantan", "country": "Malaysia", "geoPoint": {"lat": 3.8077, "lon": 103.326}}, {"city": "Melaka", "country": "Malaysia", "geoPoint": {"lat": 2.196, "lon": 102.2405}}, {"city": "Taiping", "country": "Malaysia", "geoPoint": {"lat": 4.85, "lon": 100.73333}}, {"city": "Mexico", "state": "Distrito Federal", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"city": "Tlalnepantla", "state": "Edo de Mexico", "country": "Mexico", "geoPoint": {"lat": 19.54005, "lon": -99.19538}}, {"city": "Guadalajara", "state": "Jalisco", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"city": "Monterrey", "state": "Nuevo Leon", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"city": "Huixquilucan Edo. de Mexico", "country": "Mexico"}, {"city": "Mexico City", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"city": "Auckland", "country": "New Zealand", "geoPoint": {"lat": -36.84853, "lon": 174.76349}}, {"city": "Christchurch", "country": "New Zealand", "geoPoint": {"lat": -43.53333, "lon": 172.63333}}, {"city": "Hamilton", "country": "New Zealand", "geoPoint": {"lat": -37.78333, "lon": 175.28333}}, {"city": "Otahuhu", "country": "New Zealand", "geoPoint": {"lat": -36.9382, "lon": 174.84019}}, {"city": "Palmerston North", "country": "New Zealand", "geoPoint": {"lat": -40.35636, "lon": 175.61113}}, {"city": "Takapuna", "country": "New Zealand", "geoPoint": {"lat": -36.79167, "lon": 174.77583}}, {"city": "Tauranga", "country": "New Zealand", "geoPoint": {"lat": -37.68611, "lon": 176.16667}}, {"city": "Wellington", "country": "New Zealand", "geoPoint": {"lat": -41.28664, "lon": 174.77557}}, {"city": "Chiclayo", "state": "Lambayeque", "country": "Peru", "geoPoint": {"lat": -6.77137, "lon": -79.84088}}, {"city": "Lima", "state": "San Juan de Miraflores", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"city": "Ica", "country": "Peru", "geoPoint": {"lat": -14.06777, "lon": -75.72861}}, {"city": "Manila", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"city": "Bytom", "country": "Poland", "geoPoint": {"lat": 50.34802, "lon": 18.93282}}, {"city": "Gniewkowo", "country": "Poland", "geoPoint": {"lat": 52.89461, "lon": 18.40785}}, {"city": "Krakow", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"city": "Radom", "country": "Poland", "geoPoint": {"lat": 51.40253, "lon": 21.14714}}, {"city": "Rzeszow", "country": "Poland", "geoPoint": {"lat": 50.04132, "lon": 21.99901}}, {"city": "Tychy", "country": "Poland", "geoPoint": {"lat": 50.13717, "lon": 18.96641}}, {"city": "Warszawa", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"city": "Ponce", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"city": "San Juan", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"city": "Bacau", "country": "Romania", "geoPoint": {"lat": 46.56718, "lon": 26.91384}}, {"city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"city": "Galati", "country": "Romania", "geoPoint": {"lat": 45.45, "lon": 28.05}}, {"city": "Oradea", "country": "Romania", "geoPoint": {"lat": 47.0458, "lon": 21.91833}}, {"city": "Sibiu", "country": "Romania", "geoPoint": {"lat": 45.8, "lon": 24.15}}, {"city": "Targu Mures", "country": "Romania", "geoPoint": {"lat": 46.54245, "lon": 24.55747}}, {"city": "Arkhangelsk", "country": "Russian Federation", "geoPoint": {"lat": 64.5401, "lon": 40.5433}}, {"city": "Irkutsk", "country": "Russian Federation", "geoPoint": {"lat": 52.29778, "lon": 104.29639}}, {"city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"city": "Samara", "country": "Russian Federation", "geoPoint": {"lat": 53.20007, "lon": 50.15}}, {"city": "Smolensk", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"city": "St Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"city": "Yaroslavl", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"city": "Singapore", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"city": "Port Elizabeth", "state": "Eastern Cape", "country": "South Africa", "geoPoint": {"lat": -33.91799, "lon": 25.57007}}, {"city": "Johannesburg", "state": "Gauteng", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"city": "Pretoria", "state": "Gauteng", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"city": "Durban", "state": "Kwazulu-Natal", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"city": "Tongaat", "state": "Kwazulu-Natal", "country": "South Africa", "geoPoint": {"lat": -29.57215, "lon": 31.11682}}, {"city": "Cape Town", "state": "Western Cape", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"city": "Barcelona", "state": "Catalu\u00f1a", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"city": "Santiago de Compostela", "state": "Galicia", "country": "Spain", "geoPoint": {"lat": 42.88052, "lon": -8.54569}}, {"city": "Alicante", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"city": "Amphure Muang", "country": "Thailand"}, {"city": "Bangkok", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"city": "Chiangmai", "country": "Thailand", "geoPoint": {"lat": 18.79038, "lon": 98.98468}}, {"city": "Khon Kaen", "country": "Thailand", "geoPoint": {"lat": 16.44671, "lon": 102.833}}, {"city": "Dnepropertovsk", "country": "Ukraine"}, {"city": "Dnipropetrovsk", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"city": "Lviv", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"city": "Vinnytsa", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"city": "Vinnytsya", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"city": "Zaporizhye", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"city": "Zaporizhzhya", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"city": "Aintree-Liverpool", "country": "United Kingdom"}, {"city": "Bath", "country": "United Kingdom", "geoPoint": {"lat": 51.3751, "lon": -2.36172}}, {"city": "Bournemouth", "country": "United Kingdom", "geoPoint": {"lat": 50.72048, "lon": -1.8795}}, {"city": "Dundee", "country": "United Kingdom", "geoPoint": {"lat": 56.46913, "lon": -2.97489}}, {"city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"city": "Stevenage", "country": "United Kingdom", "geoPoint": {"lat": 51.90224, "lon": -0.20256}}, {"city": "Swansea", "country": "United Kingdom", "geoPoint": {"lat": 51.62079, "lon": -3.94323}}]}, "referencesModule": {"references": [{"pmid": "27787778", "type": "DERIVED", "citation": "Gordon J, McEwan P, Hurst M, Puelles J. The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. Diabetes Ther. 2016 Dec;7(4):825-845. doi: 10.1007/s13300-016-0206-7. Epub 2016 Oct 27."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with type 2 diabetes mellitus experiencing inadequate glycemic control while on metformin therapy were enrolled equally in 1 of 3 treatment groups: alogliptin 12.5 mg once daily (QD), alogliptin 25 mg QD, and glipizide 5 mg QD.", "recruitmentDetails": "Participants took part in the study at 310 study sites worldwide from 05 March 2009 to 17 October 2012.", "groups": [{"id": "FG000", "title": "Metformin + Alogliptin 12.5 mg", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "FG001", "title": "Metformin + Alogliptin 25 mg", "description": "Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "FG002", "title": "Metformin + Glipizide", "description": "Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose \u2265250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "880"}, {"groupId": "FG001", "numSubjects": "885"}, {"groupId": "FG002", "numSubjects": "874"}]}, {"type": "Received Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "873"}, {"groupId": "FG001", "numSubjects": "878"}, {"groupId": "FG002", "numSubjects": "869"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "472"}, {"groupId": "FG001", "numSubjects": "493"}, {"groupId": "FG002", "numSubjects": "427"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "408"}, {"groupId": "FG001", "numSubjects": "392"}, {"groupId": "FG002", "numSubjects": "447"}]}], "dropWithdraws": [{"type": "Hyperglycemic rescue", "reasons": [{"groupId": "FG000", "numSubjects": "231"}, {"groupId": "FG001", "numSubjects": "201"}, {"groupId": "FG002", "numSubjects": "235"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "60"}, {"groupId": "FG001", "numSubjects": "74"}, {"groupId": "FG002", "numSubjects": "82"}]}, {"type": "Major protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "15"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "28"}]}, {"type": "Voluntary withdrawal", "reasons": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "52"}, {"groupId": "FG002", "numSubjects": "62"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Investigator discretion", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "10"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "14"}]}, {"type": "Randomized in error", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The Randomized Set included all enrolled subjects who were subsequently randomized.", "groups": [{"id": "BG000", "title": "Metformin + Alogliptin 12.5 mg", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "BG001", "title": "Metformin + Alogliptin 25 mg", "description": "Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "BG002", "title": "Metformin + Glipizide", "description": "Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose \u2265250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "880"}, {"groupId": "BG001", "value": "885"}, {"groupId": "BG002", "value": "874"}, {"groupId": "BG003", "value": "2639"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.2", "spread": "9.60"}, {"groupId": "BG001", "value": "55.5", "spread": "9.81"}, {"groupId": "BG002", "value": "55.4", "spread": "9.60"}, {"groupId": "BG003", "value": "55.4", "spread": "9.67"}]}]}]}, {"title": "Age, Customized", "description": "Categories \u226565 years and \u226575 years are not mutually exclusive. Participants \u226575 years are counted in both categories.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "734"}, {"groupId": "BG001", "value": "710"}, {"groupId": "BG002", "value": "723"}, {"groupId": "BG003", "value": "2167"}]}]}, {"title": "\u226565 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "146"}, {"groupId": "BG001", "value": "175"}, {"groupId": "BG002", "value": "151"}, {"groupId": "BG003", "value": "472"}]}]}, {"title": "\u226575 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "45"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "461"}, {"groupId": "BG001", "value": "433"}, {"groupId": "BG002", "value": "433"}, {"groupId": "BG003", "value": "1327"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "419"}, {"groupId": "BG001", "value": "452"}, {"groupId": "BG002", "value": "441"}, {"groupId": "BG003", "value": "1312"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "36"}, {"groupId": "BG003", "value": "118"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "191"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "203"}, {"groupId": "BG003", "value": "601"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "74"}, {"groupId": "BG001", "value": "66"}, {"groupId": "BG002", "value": "81"}, {"groupId": "BG003", "value": "221"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "12"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "557"}, {"groupId": "BG001", "value": "555"}, {"groupId": "BG002", "value": "533"}, {"groupId": "BG003", "value": "1645"}]}]}, {"title": "Multiracial", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "17"}, {"groupId": "BG003", "value": "42"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "192"}, {"groupId": "BG001", "value": "204"}, {"groupId": "BG002", "value": "192"}, {"groupId": "BG003", "value": "588"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "688"}, {"groupId": "BG001", "value": "681"}, {"groupId": "BG002", "value": "682"}, {"groupId": "BG003", "value": "2051"}]}]}]}, {"title": "Body Mass Index (BMI)", "description": "BMI data available for 879, 885 and 872 participants in each treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.27", "spread": "5.417"}, {"groupId": "BG001", "value": "31.27", "spread": "5.341"}, {"groupId": "BG002", "value": "31.11", "spread": "5.320"}, {"groupId": "BG003", "value": "31.22", "spread": "5.358"}]}]}]}, {"title": "Glycosylated hemoglobin (HbA1c)", "description": "Mean HbA1c data includes 877, 883 and 870 participants in each treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.59", "spread": "0.599"}, {"groupId": "BG001", "value": "7.61", "spread": "0.606"}, {"groupId": "BG002", "value": "7.60", "spread": "0.617"}, {"groupId": "BG003", "value": "7.60", "spread": "0.607"}]}]}]}, {"title": "Baseline HbA1c Category", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<8.0%", "categories": [{"measurements": [{"groupId": "BG000", "value": "615"}, {"groupId": "BG001", "value": "620"}, {"groupId": "BG002", "value": "613"}, {"groupId": "BG003", "value": "1848"}]}]}, {"title": "\u22658.0%", "categories": [{"measurements": [{"groupId": "BG000", "value": "265"}, {"groupId": "BG001", "value": "265"}, {"groupId": "BG002", "value": "261"}, {"groupId": "BG003", "value": "791"}]}]}]}, {"title": "Diabetes duration", "description": "Diabetes duration data available for 880, 884 and 874 participants in each treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.65", "spread": "5.324"}, {"groupId": "BG001", "value": "5.42", "spread": "4.730"}, {"groupId": "BG002", "value": "5.48", "spread": "4.884"}, {"groupId": "BG003", "value": "5.52", "spread": "4.985"}]}]}]}, {"title": "Metformin dose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1825.2", "spread": "405.59"}, {"groupId": "BG001", "value": "1837.2", "spread": "373.06"}, {"groupId": "BG002", "value": "1823.4", "spread": "390.63"}, {"groupId": "BG003", "value": "1828.6", "spread": "389.85"}]}]}]}, {"title": "Glomerular filtration rate", "description": "Glomerular filtration rate (GFR) was calculated using the modification of diet in renal disease (MDRD) formula and the Cockcroft-Gault formula. Data include 877, 883 and 870 participants in each treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.73m^2", "classes": [{"title": "MDRD", "categories": [{"measurements": [{"groupId": "BG000", "value": "83.04", "spread": "16.586"}, {"groupId": "BG001", "value": "82.35", "spread": "16.199"}, {"groupId": "BG002", "value": "82.28", "spread": "16.994"}, {"groupId": "BG003", "value": "82.56", "spread": "16.591"}]}]}, {"title": "Cockcroft-Gault", "categories": [{"measurements": [{"groupId": "BG000", "value": "109.3", "spread": "33.40"}, {"groupId": "BG001", "value": "109.3", "spread": "32.85"}, {"groupId": "BG002", "value": "108.0", "spread": "32.64"}, {"groupId": "BG003", "value": "108.9", "spread": "32.96"}]}]}]}, {"title": "Smoking history", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Never smoked", "categories": [{"measurements": [{"groupId": "BG000", "value": "543"}, {"groupId": "BG001", "value": "586"}, {"groupId": "BG002", "value": "578"}, {"groupId": "BG003", "value": "1707"}]}]}, {"title": "Current smoker", "categories": [{"measurements": [{"groupId": "BG000", "value": "135"}, {"groupId": "BG001", "value": "122"}, {"groupId": "BG002", "value": "111"}, {"groupId": "BG003", "value": "368"}]}]}, {"title": "Ex-smoker", "categories": [{"measurements": [{"groupId": "BG000", "value": "202"}, {"groupId": "BG001", "value": "177"}, {"groupId": "BG002", "value": "185"}, {"groupId": "BG003", "value": "564"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52", "description": "The change from Baseline to Week 52 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.", "populationDescription": "The Per-protocol set included all randomized patients who took at least 1 dose of double-blind study drug, with a Baseline assessment and at least 1 post-baseline assessment for that variable and who had no major protocol violations. Last observation carried forward (LOCF) was used.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage glycosylated hemoglobin", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Metformin + Alogliptin 12.5 mg", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG001", "title": "Metformin + Alogliptin 25 mg", "description": "Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG002", "title": "Metformin + Glipizide", "description": "Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose \u2265250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "371"}, {"groupId": "OG001", "value": "382"}, {"groupId": "OG002", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.81", "spread": "0.027"}, {"groupId": "OG001", "value": "-0.76", "spread": "0.027"}, {"groupId": "OG002", "value": "-0.73", "spread": "0.029"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "groupDescription": "The null hypotheses were tested in a fixed order at the 1-sided 0.0125 significance level at Weeks 52 and 104, independently: H01: Alogliptin 25 mg was inferior in HbA1c change from Baseline vs glipizide. H02: Alogliptin 12.5 mg was inferior vs glipizide. H03: Alogliptin 25 mg was not superior vs glipizide. H04: Alogliptin 12.5 mg was not superior vs glipizide. Each subsequent null hypothesis was tested only if all previously tested null hypotheses were rejected with respect to Weeks 52 and 104.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 25 mg and glipizide in HbA1c change from Baseline was less than 0.3%. If the null hypothesis H01 was rejected, then H02 was tested to show noninferiority of alogliptin 12.5 mg versus glipizide with a margin of 0.3%. Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 12.5 mg and glipizide in HbA1c change from Baseline was less than 0.3%.", "paramType": "LS Mean Difference", "paramValue": "-0.03", "ciPctValue": "98.75", "ciNumSides": "ONE_SIDED", "ciUpperLimit": "0.059"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 25 mg and glipizide in HbA1c change from Baseline was less than 0.3%. If the null hypothesis H01 was rejected, then H02 was tested to show noninferiority of alogliptin 12.5 mg versus glipizide with a margin of 0.3%. Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 12.5 mg and glipizide in HbA1c change from Baseline was less than 0.3%.", "paramType": "LS Mean Difference", "paramValue": "-0.09", "ciPctValue": "98.75", "ciNumSides": "ONE_SIDED", "ciUpperLimit": "0.003"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin at Other Time Points", "description": "The change from Baseline over time in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.", "populationDescription": "Per-protocol set; LOCF was used.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of glycosylated hemoglobin", "timeFrame": "Baseline and Weeks 4, 8, 12, 16, 20, 26, 39, 65, 78, and 91.", "groups": [{"id": "OG000", "title": "Metformin + Alogliptin 12.5 mg", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG001", "title": "Metformin + Alogliptin 25 mg", "description": "Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG002", "title": "Metformin + Glipizide", "description": "Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose \u2265250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "371"}, {"groupId": "OG001", "value": "382"}, {"groupId": "OG002", "value": "336"}]}], "classes": [{"title": "Week 4 (n=341, 354, 318)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.37", "spread": "0.020"}, {"groupId": "OG001", "value": "-0.40", "spread": "0.020"}, {"groupId": "OG002", "value": "-0.41", "spread": "0.021"}]}]}, {"title": "Week 8 (n=370, 382, 336)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.56", "spread": "0.024"}, {"groupId": "OG001", "value": "-0.60", "spread": "0.024"}, {"groupId": "OG002", "value": "-0.66", "spread": "0.025"}]}]}, {"title": "Week 12 (n=371, 382, 336)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.69", "spread": "0.025"}, {"groupId": "OG001", "value": "-0.71", "spread": "0.025"}, {"groupId": "OG002", "value": "-0.78", "spread": "0.026"}]}]}, {"title": "Week 16 (n=371, 382, 336)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.74", "spread": "0.026"}, {"groupId": "OG001", "value": "-0.76", "spread": "0.025"}, {"groupId": "OG002", "value": "-0.78", "spread": "0.027"}]}]}, {"title": "Week 20 (n=371, 382, 336)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.76", "spread": "0.026"}, {"groupId": "OG001", "value": "-0.78", "spread": "0.025"}, {"groupId": "OG002", "value": "-0.79", "spread": "0.027"}]}]}, {"title": "Week 26 (n=371, 382, 336)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.80", "spread": "0.027"}, {"groupId": "OG001", "value": "-0.79", "spread": "0.026"}, {"groupId": "OG002", "value": "-0.80", "spread": "0.028"}]}]}, {"title": "Week 39 (n=371, 382, 336)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.81", "spread": "0.026"}, {"groupId": "OG001", "value": "-0.81", "spread": "0.025"}, {"groupId": "OG002", "value": "-0.74", "spread": "0.027"}]}]}, {"title": "Week 65 (n=371, 382, 336)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.81", "spread": "0.029"}, {"groupId": "OG001", "value": "-0.83", "spread": "0.028"}, {"groupId": "OG002", "value": "-0.76", "spread": "0.030"}]}]}, {"title": "Week 78 (n=371, 382, 336)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.82", "spread": "0.030"}, {"groupId": "OG001", "value": "-0.80", "spread": "0.030"}, {"groupId": "OG002", "value": "-0.73", "spread": "0.032"}]}]}, {"title": "Week 91 (n=371, 382, 336)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.76", "spread": "0.033"}, {"groupId": "OG001", "value": "-0.77", "spread": "0.033"}, {"groupId": "OG002", "value": "-0.68", "spread": "0.035"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose Over Time", "description": "The change from Baseline in fasting plasma glucose (FPG) was assessed at Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104. LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline FPG and Baseline metformin dose as covariates.", "populationDescription": "Full analysis set, which included all randomized patients who received at least 1 dose of double-blind study drug who had a Baseline assessment and at least 1 post-baseline assessment for FPG. LOCF was used.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104.", "groups": [{"id": "OG000", "title": "Metformin + Alogliptin 12.5 mg", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG001", "title": "Metformin + Alogliptin 25 mg", "description": "Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG002", "title": "Metformin + Glipizide", "description": "Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose \u2265250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "867"}, {"groupId": "OG001", "value": "867"}, {"groupId": "OG002", "value": "859"}]}], "classes": [{"title": "Week 2 (n=781, 803, 777)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.2", "spread": "0.89"}, {"groupId": "OG001", "value": "-11.4", "spread": "0.87"}, {"groupId": "OG002", "value": "-7.7", "spread": "0.89"}]}]}, {"title": "Week 4 (n=863, 865, 855)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.6", "spread": "0.85"}, {"groupId": "OG001", "value": "-11.6", "spread": "0.85"}, {"groupId": "OG002", "value": "-10.2", "spread": "0.85"}]}]}, {"title": "Week 8 (n=867, 867, 859)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.2", "spread": "0.91"}, {"groupId": "OG001", "value": "-11.6", "spread": "0.91"}, {"groupId": "OG002", "value": "-9.3", "spread": "0.92"}]}]}, {"title": "Week 12 (n=867, 867, 859)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.7", "spread": "0.94"}, {"groupId": "OG001", "value": "-11.2", "spread": "0.94"}, {"groupId": "OG002", "value": "-9.4", "spread": "0.95"}]}]}, {"title": "Week 16 (n=867, 867, 859)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.6", "spread": "0.98"}, {"groupId": "OG001", "value": "-9.9", "spread": "0.98"}, {"groupId": "OG002", "value": "-7.1", "spread": "0.98"}]}]}, {"title": "Week 20 (n=867, 867, 859)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.6", "spread": "1.02"}, {"groupId": "OG001", "value": "-10.1", "spread": "1.02"}, {"groupId": "OG002", "value": "-5.5", "spread": "1.02"}]}]}, {"title": "Week 26 (n=867, 867, 859)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.5", "spread": "1.06"}, {"groupId": "OG001", "value": "-10.1", "spread": "1.06"}, {"groupId": "OG002", "value": "-4.3", "spread": "1.06"}]}]}, {"title": "Week 39 (n=867, 867, 859)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.9", "spread": "1.14"}, {"groupId": "OG001", "value": "-8.4", "spread": "1.14"}, {"groupId": "OG002", "value": "-0.6", "spread": "1.15"}]}]}, {"title": "Week 52 (n=867, 867, 859)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.0", "spread": "1.22"}, {"groupId": "OG001", "value": "-7.0", "spread": "1.22"}, {"groupId": "OG002", "value": "0.9", "spread": "1.23"}]}]}, {"title": "Week 65 (n=867, 867, 859)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.4", "spread": "1.21"}, {"groupId": "OG001", "value": "-5.9", "spread": "1.21"}, {"groupId": "OG002", "value": "1.4", "spread": "1.21"}]}]}, {"title": "Week 78 (n=867, 867, 859)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.8", "spread": "1.47"}, {"groupId": "OG001", "value": "-5.1", "spread": "1.47"}, {"groupId": "OG002", "value": "5.1", "spread": "1.48"}]}]}, {"title": "Week 91 (n=867, 867, 859)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "1.27"}, {"groupId": "OG001", "value": "-3.4", "spread": "1.27"}, {"groupId": "OG002", "value": "4.9", "spread": "1.28"}]}]}, {"title": "Week 104 (n=867, 867, 859)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "1.28"}, {"groupId": "OG001", "value": "-3.2", "spread": "1.28"}, {"groupId": "OG002", "value": "5.4", "spread": "1.29"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%", "description": "The percentage of participants with HbA1c less than or equal to 6.5% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.", "populationDescription": "Full analysis set. Participants who did not complete the scheduled Week 26, Week 52, Week 78 or Week 104 visit were assessed based on their response at the time of discontinuation.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 26, 52, 78, and 104.", "groups": [{"id": "OG000", "title": "Metformin + Alogliptin 12.5 mg", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG001", "title": "Metformin + Alogliptin 25 mg", "description": "Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG002", "title": "Metformin + Glipizide", "description": "Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose \u2265250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "873"}, {"groupId": "OG001", "value": "878"}, {"groupId": "OG002", "value": "869"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "25.6"}, {"groupId": "OG001", "value": "26.2"}, {"groupId": "OG002", "value": "24.8"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.5"}, {"groupId": "OG001", "value": "24.8"}, {"groupId": "OG002", "value": "20.8"}]}]}, {"title": "Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.2"}, {"groupId": "OG001", "value": "26.4"}, {"groupId": "OG002", "value": "21.8"}]}]}, {"title": "Week 104", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.5"}, {"groupId": "OG001", "value": "24.1"}, {"groupId": "OG002", "value": "19.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%", "description": "Percentage of participants with HbA1c \u2264 7.0% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.", "populationDescription": "Full analysis set. Participants who did not complete the scheduled Week 26, Week 52, Week 78 or Week 104 visit were assessed based on their response at the time of discontinuation.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 26, 52, 78, and 104.", "groups": [{"id": "OG000", "title": "Metformin + Alogliptin 12.5 mg", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG001", "title": "Metformin + Alogliptin 25 mg", "description": "Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG002", "title": "Metformin + Glipizide", "description": "Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose \u2265250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "873"}, {"groupId": "OG001", "value": "878"}, {"groupId": "OG002", "value": "869"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "56.4"}, {"groupId": "OG001", "value": "59.2"}, {"groupId": "OG002", "value": "56.1"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "51.7"}, {"groupId": "OG001", "value": "55.5"}, {"groupId": "OG002", "value": "47.4"}]}]}, {"title": "Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "48.8"}, {"groupId": "OG001", "value": "52.4"}, {"groupId": "OG002", "value": "46.6"}]}]}, {"title": "Week 104", "categories": [{"measurements": [{"groupId": "OG000", "value": "45.6"}, {"groupId": "OG001", "value": "48.5"}, {"groupId": "OG002", "value": "42.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight Over Time", "description": "LS Means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and Baseline weight and Baseline metformin dose as covariates.", "populationDescription": "Full analysis set, LOCF was used.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "Baseline and Weeks 12, 26, 39, 52, 65, 78, 91, and 104.", "groups": [{"id": "OG000", "title": "Metformin + Alogliptin 12.5 mg", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG001", "title": "Metformin + Alogliptin 25 mg", "description": "Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG002", "title": "Metformin + Glipizide", "description": "Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose \u2265250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "867"}, {"groupId": "OG001", "value": "868"}, {"groupId": "OG002", "value": "861"}]}], "classes": [{"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.51", "spread": "0.076"}, {"groupId": "OG001", "value": "-0.53", "spread": "0.076"}, {"groupId": "OG002", "value": "0.71", "spread": "0.077"}]}]}, {"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.65", "spread": "0.101"}, {"groupId": "OG001", "value": "-0.71", "spread": "0.101"}, {"groupId": "OG002", "value": "0.86", "spread": "0.101"}]}]}, {"title": "Week 39", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.60", "spread": "0.109"}, {"groupId": "OG001", "value": "-0.86", "spread": "0.109"}, {"groupId": "OG002", "value": "0.97", "spread": "0.110"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.63", "spread": "0.117"}, {"groupId": "OG001", "value": "-0.90", "spread": "0.117"}, {"groupId": "OG002", "value": "0.89", "spread": "0.117"}]}]}, {"title": "Week 65", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.70", "spread": "0.122"}, {"groupId": "OG001", "value": "-0.92", "spread": "0.122"}, {"groupId": "OG002", "value": "0.87", "spread": "0.123"}]}]}, {"title": "Week 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.78", "spread": "0.124"}, {"groupId": "OG001", "value": "-0.94", "spread": "0.124"}, {"groupId": "OG002", "value": "0.88", "spread": "0.125"}]}]}, {"title": "Week 91", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.67", "spread": "0.127"}, {"groupId": "OG001", "value": "-0.88", "spread": "0.127"}, {"groupId": "OG002", "value": "0.89", "spread": "0.127"}]}]}, {"title": "Week 104", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.68", "spread": "0.127"}, {"groupId": "OG001", "value": "-0.89", "spread": "0.127"}, {"groupId": "OG002", "value": "0.95", "spread": "0.127"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104", "description": "The change from Baseline to Week 104 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.", "populationDescription": "The Per-protocol set included all randomized patients who took at least 1 dose of double-blind study drug, with a Baseline assessment and at least 1 post-baseline assessment for that variable and who had no major protocol violations. Last observation carried forward was used (LOCF).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage glycosylated hemoglobin", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Metformin + Alogliptin 12.5 mg", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG001", "title": "Metformin + Alogliptin 25 mg", "description": "Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks."}, {"id": "OG002", "title": "Metformin + Glipizide", "description": "Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose \u2265250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "371"}, {"groupId": "OG001", "value": "382"}, {"groupId": "OG002", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.68", "spread": "0.037"}, {"groupId": "OG001", "value": "-0.72", "spread": "0.037"}, {"groupId": "OG002", "value": "-0.59", "spread": "0.039"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "groupDescription": "The null hypotheses were tested in a fixed order at the 1-sided 0.0125 significance level at Weeks 52 and 104, independently: H01: Alogliptin 25 mg was inferior in HbA1c change from Baseline vs glipizide. H02: Alogliptin 12.5 mg was inferior vs glipizide. H03: Alogliptin 25 mg was not superior vs glipizide. H04: Alogliptin 12.5 mg was not superior vs glipizide. Each subsequent null hypothesis was tested only if all previously tested null hypotheses were rejected with respect to Weeks 52 and 104.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 25 mg and glipizide in HbA1c change from Baseline was less than 0.3%. If the null hypothesis H01 was rejected, then H02 was tested to show noninferiority of alogliptin 12.5 mg versus glipizide with a margin of 0.3%. Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 12.5 mg and glipizide in HbA1c change from Baseline was less than 0.3%.", "paramType": "LS Mean Difference", "paramValue": "-0.13", "ciPctValue": "98.75", "ciNumSides": "ONE_SIDED", "ciUpperLimit": "-0.006"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 25 mg and glipizide in HbA1c change from Baseline was less than 0.3%. If the null hypothesis H01 was rejected, then H02 was tested to show noninferiority of alogliptin 12.5 mg versus glipizide with a margin of 0.3%. Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 12.5 mg and glipizide in HbA1c change from Baseline was less than 0.3%.", "paramType": "LS Mean Difference", "paramValue": "-0.09", "ciPctValue": "98.75", "ciNumSides": "ONE_SIDED", "ciUpperLimit": "0.035"}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Collection of adverse events commenced from the time the participant was first administered double-blind study medication until the end of the study and from spontaneous reporting for 30 days after the end of treatment (up to 108 weeks).", "description": "At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.", "eventGroups": [{"id": "EG000", "title": "Metformin + Alogliptin 12.5 mg", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.", "seriousNumAffected": 86, "seriousNumAtRisk": 873, "otherNumAffected": 688, "otherNumAtRisk": 873}, {"id": "EG001", "title": "Metformin + Alogliptin 25 mg", "description": "Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.", "seriousNumAffected": 97, "seriousNumAtRisk": 878, "otherNumAffected": 687, "otherNumAtRisk": 878}, {"id": "EG002", "title": "Metformin + Glipizide", "description": "Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose \u2265250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.", "seriousNumAffected": 81, "seriousNumAtRisk": 869, "otherNumAffected": 668, "otherNumAtRisk": 869}], "seriousEvents": [{"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 869}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 869}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 869}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 869}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 869}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 869}]}, {"term": "Atrioventricular block complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Silent myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Arteriosclerosis coronary artery", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Atrioventricular block", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Atrioventricular block second degree", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Congestive cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Coronary artery occlusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Pericardial effusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Right ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Tachyarrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 869}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 869}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Dengue fever", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 869}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Hepatitis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 869}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Abdominal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Abscess limb", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Amoebiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Gangrene", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Gastroenteritis salmonella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Lobar pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Malaria", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Pneumocystis jiroveci pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Scrotal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Staphylococcal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 869}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Carotid artery stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Haemorrhagic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Intercostal neuralgia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Neuralgia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Parkinsonism", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Tension headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "VIIth nerve paralysis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "VIth nerve paralysis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Vertebrobasilar insufficiency", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 869}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Muscle haemorrhage", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Haemarthrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Myalgia intercostal", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Polymyositis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Spinal column stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Colitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 869}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Anal fistula", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Colitis ischaemic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Diverticulum", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Enterocolitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Haematemesis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Intestinal ischaemia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Mallory-Weiss syndrome", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Umbilical hernia, obstructive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Adenocarcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Bladder transitional cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Colon adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Colon cancer stage 0", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Endometrial cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Gastrointestinal tract adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Lipoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Lung adenocarcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Non-Hodgkin's lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Non-small cell lung cancer stage IIIB", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Ovarian adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Ovarian cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Rectal cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Renal oncocytoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Small cell lung cancer stage unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Squamous cell carcinoma of skin", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 869}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Comminuted fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Craniocerebral injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Facial bones fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Incisional hernia", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Joint dislocation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Ligament rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Patella fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Peripheral nerve injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 869}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Calculus urinary", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Diabetic nephropathy", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Aortic aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Arterial thrombosis limb", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Embolism", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Femoral artery occlusion", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Iliac artery occlusion", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Thrombophlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 869}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Hernia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Acute pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Emphysema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Granulomatous pneumonitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Interstitial lung disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Pleuritic pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Adenomyosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Cervical dysplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Cervix disorder", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Cystocele", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Epididymitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Metrorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Rectocele", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Uterine prolapse", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Uterovaginal prolapse", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Bile duct stone", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Drug-induced liver injury", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Cataract nuclear", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Cataract subcapsular", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Iridocyclitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Retinal detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Bipolar disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Alcohol withdrawal syndrome", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Depressed mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Schizophrenia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Acute vestibular syndrome", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Vertigo positional", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Iron deficiency anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Primary hyperaldosteronism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}, {"term": "Abortion", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 869}]}, {"term": "Rash maculo-papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 869}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 60, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 60, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 63, "numAtRisk": 869}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 84, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 90, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 76, "numAtRisk": 869}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 78, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 67, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 61, "numAtRisk": 869}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 37, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 32, "numAtRisk": 869}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 32, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 20, "numAtRisk": 869}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 28, "numAtRisk": 869}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 27, "numAtRisk": 869}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 36, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 36, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 42, "numAtRisk": 869}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 41, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 33, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 38, "numAtRisk": 869}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 39, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 36, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 36, "numAtRisk": 869}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 29, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 23, "numAtRisk": 869}]}, {"term": "Creatinine renal clearance decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 34, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 32, "numAtRisk": 869}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 91, "numAtRisk": 869}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 34, "numAtRisk": 869}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 54, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 45, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 49, "numAtRisk": 869}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 38, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 42, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 40, "numAtRisk": 869}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 33, "numAtRisk": 869}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 45, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 60, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 46, "numAtRisk": 869}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 29, "numAtRisk": 869}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 29, "numAtRisk": 869}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 35, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 26, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 33, "numAtRisk": 869}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 45, "numAtRisk": 873}, {"groupId": "EG001", "numAffected": 67, "numAtRisk": 878}, {"groupId": "EG002", "numAffected": 65, "numAtRisk": 869}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The Week 52 results summarized in herein differ from the Week 52 results summarized in an interim analysis, because the per protocol set (PPS) defined for the final analysis included fewer subjects than the PPS defined for the interim analysis."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."}, "pointOfContact": {"title": "Medical Director, Clinical Science", "organization": "Takeda", "email": "clinicaltrialregistry@tpna.com", "phone": "800-778-2860"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M20295", "name": "Glucose Intolerance", "relevance": "LOW"}, {"id": "M9994", "name": "Hyperglycemia", "relevance": "LOW"}, {"id": "M9997", "name": "Hyperinsulinism", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000520853", "term": "Alogliptin"}, {"id": "D000005913", "term": "Glipizide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M9023", "name": "Glipizide", "asFound": "Xylocaine", "relevance": "HIGH"}, {"id": "M247106", "name": "Alogliptin", "asFound": "Reflex", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}